• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MapLight Therapeutics, Inc. - Common Stock (NQ:MPLT)

    13.15 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 13.15
    Bid (Size) 12.36 (200)
    Ask (Size) 13.75 (100)
    Prev. Close 13.15
    Today's Range 13.15 - 13.15
    52wk Range 9.100 - 40.43
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    MapLight Therapeutics to Participate in Upcoming Investor Conference
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -21.6%
    -21.6%
    1 Month
    +16.9%
    +16.9%
    3 Month
    -53.0%
    -53.0%
    6 Month
    -30.4%
    -30.4%
    1 Year
    -28.3%
    -28.3%

    More News

    Read More
    News headline image
    MapLight Therapeutics Announces $150 Million Private Placement Financing
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    Top movers analysis one hour before the close of the markets on 2026-07-29: top gainers and losers in today's session. ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Wednesday's session. ↗
    Via Chartmill
    Which stocks are moving on Monday? ↗
    Via Chartmill
    News headline image
    Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint ↗
    Via MarketBeat
    Monday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    These stocks that are showing activity before the opening bell on Monday. ↗
    Via Chartmill
    News headline image
    MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Therapeutics Announces Changes to Board of Directors
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
    Via The Motley Fool
    News headline image
    Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
    Via The Motley Fool
    News headline image
    MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? ↗
    Via The Motley Fool
    Topics Derivatives Regulatory Compliance
    News headline image
    MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Therapeutics to Participate in Upcoming Investor Conferences
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April ↗
    Via The Motley Fool
    Topics Derivatives Regulatory Compliance
    News headline image
    MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is MapLight Therapeutics, Inc. - Common Stock publicly traded?
    Yes, MapLight Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does MapLight Therapeutics, Inc. - Common Stock trade on?
    MapLight Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MapLight Therapeutics, Inc. - Common Stock?
    The ticker symbol for MapLight Therapeutics, Inc. - Common Stock is MPLT on the Nasdaq Stock Market
    What is the current price of MapLight Therapeutics, Inc. - Common Stock?
    The current price of MapLight Therapeutics, Inc. - Common Stock is 13.15
    When was MapLight Therapeutics, Inc. - Common Stock last traded?
    The last trade of MapLight Therapeutics, Inc. - Common Stock was at 09/14/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.